The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

As of Wednesday, Jan. 14, the Moon phase is Waning Crescent. According to NASA's Daily Moon Guide, 17% of the Moon will be ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...

The Moon is moving during the waning crescent phase. It will stay there till 5:52 PM before moving to Dwadashi, earlier ...

The biggest stories of the day delivered to your inbox.